Research Article
Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis
Table 2
Percentage frequency of the other baseline characteristics of patients who received anthracycline chemotherapy.
| | Nottingham grade of cancer | 2nd line drugs received (this is given after the three weeks of completion of anthracycline chemotherapy) |
| | Low nuclear grade in situ CA | 0.5% | None | 2.6% | | Grade I | 15.3% | Docetaxel | 65.3% | | Grade II | 51.5% | Paclitaxel | 23.4% | | Grade III | 32.7% | Nano paclitaxel | 8.7% |
| | Type of anthracycline | Blood relatives | | Doxorubicin | 80.1% | With cancer | 24.0% | | Epirubicin | 19.9% | Without cancer | 76.0% |
| | Number of anthracycline cycles given | Marital states | | 04 cycles | 98.5% | Married | 75.5% | | 06 cycles | 1.5% | Unmarried | 24.5% |
| | Patients with | Receptor status | | Diabetes mellitus | 42.9% | ER positives | 25.5% | | Dyslipidemia | 35.2% | PR positives | 19.4% | | Neither | 21.9% | Her 2 positives | 1.0% | | | ER and PR positives | 48.0% | | | ER and Her 2 positives | 3.1% | | | PR and Her 2 positives | 1.5% | | | ER, PR, and Her 2 positives | 1.5% |
|
|
CA: carcinoma; ER: estrogen receptor; PR: progesterone receptor; Her 2: human epidermal growth factor receptor 2.
|
